BLU 285 companion diagnostic - Blueprint Medicines/QIAGEN

Drug Profile

BLU 285 companion diagnostic - Blueprint Medicines/QIAGEN

Alternative Names: BLU-285 companion diagnostic - Blueprint Medicines/QIAGEN

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blueprint Medicines; QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Gastrointestinal stromal tumours

Most Recent Events

  • 22 Aug 2016 Blueprint Medicines and QIAGEN agree to co-develop and co-promote BLU 285 companion diagnostic in countries worldwide, primarily USA, European Union and Canada for Gastrointestinal stromal tumor (Diagnosis) (Blueprint Medicines Form 8-K, August 2016),
  • 22 Aug 2016 Early research in Gastrointestinal stromal tumours (Diagnosis) in Germany and USA (unspecified route) (Blueprint Medicines Form 8-K, August 2016),
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top